Europe Ocular Drug Delivery Market Trends and Analysis by 2028

The ocular drug delivery market in Europe is expected to grow to US$ 7,921.15 million by 2028 from US$ 4,967.64 million in 2021. The market is estimated to grow at a CAGR of 6.9% from 2021 to 2028.

The incidence of eye diseases has increased significantly. In recent years, various measures and efforts have been taken to create awareness and educate people regarding eye diseases, facilitating patients access to suitable medications and treatments for such conditions. Sightsavers—an international non-governmental organization—works in developing countries to treat and prevent eye diseases. A large population of India resides in rural areas, which has limited or no awareness about eye ailments. With its Rural Eye Health Programme, Sightsavers aims to create awareness, provide high-quality eye health services, and eradicate avoidable blindness in the rural population. Thus, the growing eye health awareness programs are likely to create growth opportunities for the market.

The European region has been massively hit by the COVID-19 spread, with most countries being in lockdown. Routine healthcare services were cancelled, and patients were recommended to avoid hospital visits to minimize the risk of COVID-19 transmission, leading to significant disruption to the provision of healthcare service and patient care. Ophthalmology represents one of the busiest and heavily outpatient-oriented specialties, with around 7.5 million outpatient appointments and over 500,000 surgical procedures being conducted every year in the United Kingdom. The lockdown has resulted in the cancellation of thousands of ophthalmic visits and surgeries; this has potentially led to permanent and significant harm to patient’s vision. Additionally, as per the recent survey – ‘Psychosocial impact of COVID-19 pandemic lockdown on people living with eye diseases in the UK’ which was conducted among the public with eye diseases, highlighted a significant negative psychosocial impact of lockdown on patients with visual impairment, with approximately 50% of the patients express fear of sight loss due to delayed review or treatment.

With the new features and technologies, companies can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the ocular drug delivery market. The Europe ocular drug delivery market is expected to grow at a good CAGR during the forecast period.

Europe Ocular Drug Delivery Market Segmentation

 

Europe Ocular Drug Delivery Market – By Technology

• Implantable Ocular Drug Delivery Systems
• Particulate Drug Delivery Systems
• Nano-Particle Drug Delivery System
• Others

Europe Ocular Drug Delivery Market – By Formulation Type

• Solution
• Ointment
• Suspension
• Emulsion
• Liposomes and Nanoparticles

Europe Ocular Drug Delivery Market – By Disease type

• Cataract
• Dry Eye Syndrome
• Macular Degeneration
• Glaucoma
• Diabetic Retinopathy
• Diabetic Macular Edema
• Others

Europe Ocular Drug Delivery Market – By End User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Europe Ocular Drug Delivery Market – By Country

• Germany
• France
• United Kingdom
• Italy
• Spain
• Rest of Europe

Europe Ocular Drug Delivery Market – Companies Mentioned

• AbbVie Inc.                                              
• Bausch Health Companies Inc.            
• Novartis AG                                            
• Clearside Biomedical, Inc                       
• Alimera Sciences, Inc.                           
• GRAYBUG VISION, INC

Europe Ocular Drug Delivery Report Scope